Swiss biotech start-up. We?re using our Antibody-Catch? technology to develop accurate treatments for rare autoimmune disorders. Polyneuron is an early stage Swiss pharmaceutical company (spin-off from the University of Basel) is developing antibodies targeting autoimmune diseases of the peripheral nervous system.
Polyneuron Pharmaceuticals AG
[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/polyneuron-pharmaceuticals” connections=”true” suffix=””]
Polyneurons Antibody-Catchë platform technology enables the development of antibody-specific immunotherapy for autoimmune diseases involving antibodies against glyco-epitopes.
May 2018, Polyneurons completes CHF 3.1 M seed financing. The financing was led by EVA Basel and included the ZÈrcher Kantonalbank and private investors.
In Jun 2015, Polyneuron received 130,000 francs as a starting capital from Venture Kick.